“This document contains "forward-looking statements" - that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties which could adversely or positively affect our future results include: the behavior of financial markets, including fluctuations in interest rates and commodity prices; strategic actions, including dispositions; future integration of acquired businesses; future financial performance of major industries which we serve, including, without limitation, the air and rail transportation, energy generation, media, real estate and healthcare industries; unanticipated loss development in our insurance businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive and regulatory nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

Healthcare Re-imagined

Reinaldo GarciaPresident & CEOGE Healthcare InternationalSept 6, 2006

2 /

Key messages for today

• GE Healthcare is uniquely positioned in a great space

• A clear vision built on a strong foundation

• Physics + Biology + IT = new age of diagnostics

• GE Healthcare to grow by improving industry efficiency and efficacy

3 /

GE Healthcare

$17B global business unit of GE

$1B+/year in R&D investment

45,000 employees worldwide

Core strengths in Bio-Sciences, Technology, Services

GE heritage for vision and execution

Only GE

Three complementary platforms … creating new markets

Medical Diagnostics

• Contrast agents• Molecular diagnostics

Information Technology & Services

•Electronic medical records•Revenue cycle

Diagnostic Imaging

• CT, PET/CT• MR, X-Ray

•Performance solutions•Multi-vendor services

Life Sciences

•Discovery systems•Protein separations

Clinical Systems

• Ultrasound• Critical care systems

Broad Based Diagnostics

5 /

Healthcare Re-ImaginedWe strive to see life more clearly. Our Purpose is to

help predict, diagnose, treat and monitor disease earlier so people can live life to the fullest

"Early Health"Prevention/PredictionDetailed Patient InfoEarly DiagnosisTargeted Therapies

"Late Disease"Symptom BasedIncomplete Data Managing IllnessStandardized treatment

From To

Driving clinical efficacy & Healthcare system efficiency

6 /

Molecular medicine: The right next stepEf

ficie

ncy

Molecular imaging (2000+)Biology, Nanotech, CAD

Analog (00 to 80’s) X-ray & Paper

Digital (80’s to 90’s)CT, MR, PACS

Sensitivity& specificity

Clinical certainty

7 /

GE Healthcare Molecular Imaging Capabilities

Diagnostic ImagingClinical ImagingPre-clinical ImagingPet Radiopharmacy

Life ScienceProtein SeparationsGene Expression technology

Medical DiagnosticsContrast AgentsRadiopharmaceuticalsGenomics, Proteomics &Cellular Biomarkers

Academic CollborationsStanford UniversityMD Anderson Cancer CenterHarvard Medical Shool

Pharma PartnershipsEli LillyPfizerRoche

New Tracer DevelopmentPIBMIBG

Clinical TrialsPET Investigation Network (PIN)

ImanetHammersmith, UKUppsala, SwedenTurku, Finland

Global Research CentersImaging TechnologyTargeted Agents2500 ScientistsChina, India, Germany, USA

Information TechnologyComputer Aided detectionIntegrated InformaticsElectronic Medical Records w/ Gene pre-disposition

ImanetNetwork of molecular ImagingResearch & development Centers20+ clinical PET tracers

GE Healthcare Business Platforms

Three complementary platforms … creating new markets

Medical Diagnostics

• Contrast agents• Molecular diagnostics

Information Technology & Services

•Electronic medical records•Revenue cycle

Diagnostic Imaging

• CT, PET/CT• MR, X-Ray

•Performance solutions•Multi-vendor services

Life Sciences

•Discovery systems•Protein separations

Clinical Systems

• Ultrasound• Critical care systems

Broad Based Diagnostics

9GE Healthcare

DI: Strong global growth opportunity

11% AAGR/ Growth

CT

MR

X-ray

FI

2006E

~$5+

1998

$2.4

($B)

$2.5+B of Organic Growth Technology Leadership

Other

CT… #1 market position• New products: BrightSpeed

Nuclear Medicine/PET… #1 market position• New products: Infinia Hawkeye

MR… #1 market position •New products: HDe, HDx 1.5T and 3.0T

X-ray… #2 market position • New products: Seno Essential, Definium 6000

Driving clinical efficacy

10GE Healthcare

… a massive growth opportunity and health impact by accessing

“asymptomatic” population

A big market in a “symptomatic” disease management paradigm

Cardiac disease

Alzheimer’s disease

Colon cancer

Breast cancerBreast

Colon

Brain

Heart

Improving patient care and Healthcare economics

CardiologySudden cardiac death is 1st clue of underlying heart disease for 50% patientsCVD causes 4.3 million deaths per year in EuropeCVD costs EU economy €169 billion p.a.

Colon Cancer5-year survival of 90% for those diagnosed early – localized disease5-year survival drops to 66% when cancer is locally advanced5-year survival only 8.5% if cancer spreads (metastatic disease)

DI: From Late Disease to Early Health

11GE Healthcare

SPECT

CTUltrasound

MRI

TargetedSPECT

PET

Spanning anatomical to functional images

18FDG

GenomicsProteomics

Molecular Targets & Receptors

Molecular Pathways

Pre-disposition

Cath/ EP Intervention

Diagnostics &Therapy

MetabolismViability

PerfusionFunction

Anatomy

12GE Healthcare

Moderate(Symptomatic)

Severe(CHF)

Mild(Asymptomatic)

General PracticeFamily PracticeInternal Medicine

CardiologistEchocardiographer, Nuclear

InterventionalCardiac Surgeon

MedicalStatins

Behavior modification

Non-surgical InterventionPTCA CABGStenting

SurgicalICD

Transplantation

Pre-test probabilityRisk factorsCalcium Score

Cardiac FunctionPerfusion & ViabilityCoronary anatomy

ViabilityInnervation

VisipaqueVCT

OptisonU/S

MyoviewSPECT

Thallium-201SPECT

VisipaqueCath

Biopsy

OmniScanMRI AdreView

SPECT

Myoview (Dual Isotope)

CZT SPECT

MyoviewSPECTVulnerable

PlaqueSPECT Omnipaque

Cath

Cardio focus: Medical Diagnostics for each stage of detection

DiseaseState

Prognostic Data

Physician

GE ProductFit

Therapy

13GE Healthcare

Medical Diagnostics targeting Neuro: Next $1B imaging market

US incidence

(MM)

DATSCAN

high

low

Alzheimers6.7

Epilepsy3.0

Stroke5.7

1.6

Referring physicians& imaging specialists

Stroke4.5

Alzheimers4.3

Mood disorders25

Parkinsons1.0

Epilepsy2.3

2005 2010

Mood disorders30

Clinical Need Driving the DaTSCAN* Clinical Program• DaTSCAN images dopamine

transporters in brain…sensitivity differentiates diagnosis for both Parkinson’s and Dementia with Lewy bodies

• DaTSCAN results in fewer patients treated with inappropriate therapy

• DaTSCAN growth in Europe $20MM in 2 years

• Pursuing Parkinson’s product in USLate stage PS

Normal Patient

Report published

0

10

20

30

40

50

60 Reimbursement Granted

Parkinsons

*Source: Health Economic Research Project, “An assessment of the cost-effectiveness of DaTSCAN SPECT for the diagnosis of patients with clinically uncertain Parkinsonism.” Approved in EU only.

Creating a market in Parkinson’s and Dementia with Lewy bodies

2004 Weekly DaTSCAN Sales in Belgium

14GE Healthcare

14%AAGR

Clinical Systems

• High “patient touch”• Diverse portfolio of leading brands• Broad footprint in hospital and non-hospital segments• International growth

Keys to successValue creation

Product breadth

Cost management

Balanced investment

GE Ultrasound ($B)

MonitoringSolutions

Life SupportSolutions

Ultrasound

ServicesDiagnosticCardiology

BoneDensitometry

MaternalInfant Care

Revenues

‘00 ’06E

$0.8

$1.7

Revenues: $3.7B

15GE Healthcare

Ultrasound Leadership: A global technology migration

Radiology/emerging OB/Gyn Cardiovascular

LOGIQ 9

LOGIQ 7

LOGIQ S6

LOGIQ P5

LOGIQ 5

LOGIQ 3

LOGIQ i

LOGIQ e

Voluson 730E

Voluson 730P

Voluson 730PV

Voluson i Vivid 7

Vivid 4

Vivid 3

Vivid i

Vivid e

6 new platforms in 2006

’06 new platform

LOGIQ 9400 lbs.

LOGIQ e10 lbs.

Customer value creation• Value for traditional and

new customers

Product breadth• Software-based platform• Clinical applications

Cost management• Global COE• Annual ICV targets

Balanced investment• Miniaturization “big swing”

platform

Sales

‘02 ’06E

$5

($ MM)

GE Compact Ultrasound Series

Product breadth

Start-up to $200M in 3 years

Compact Ultrasound

$180

16GE Healthcare

$40B+ in 2005

Healthcare IT is "HOT"

CXO

IT’s all about …• Quality • Safety• Workflow

IT’s all driven by …• Growth in outpatient services • National programs …

UK & Canada• Pay for performance • Continuity of care

IT’s a growth opportunity …• EHR in < 20% physician offices• #1 priority for CXOs

• IT improves clinical efficacy & lowers healthcare costs

• $40+B segment is growing at double-digit rate

• GE has a broad suite of products & services …#1 in the space

• GE is well positioned for growth

17 /

Hours of antibiotic therapy Days in hospitalCosts for hospital

w/IT Assistant

10310

$26K

base

33017

$44K

Healthcare IT … a practical example

70%40%40%

From Paper

Outcomes published … New England Journal of Medicine

to Digital with improved clinical information

Better patient outcomes at

lower cost

18GE Healthcare

Building a World-class HCIT business

2000 2002 2004 2006 E

Physician OfficeAdmin/HIS

In-Patient

Imaging &Clinical Apps

$370

$605

$930

~$1.9B• 30% CAGR … 17% organic growth• >1,500 facilities ... >35 countries

DeviceIntegration

ClinicalDepartments

PhysicianOffices

ClinicalContent Workflow

PACS EHR

($MM)

New business

New customers

Commercial wins

New products

19GE Healthcare

GE Healthcare Services Growth

$0.8

$3.0

2000 2005 CAGR%

Healthcare IT 30+

Performance solutions 40+

Contract services 10

Install base & software 10+

Refurbishment 15+

‘95 ‘00 ‘05

$5.4Revenue($ in billions)

Services growth … ~7X in last 10 years

20GE Healthcare

Life SciencesKey Drivers• Pharma growth in Monoclonal antibody

therapy & Vaccine pipelines

• Biotech R&D spend increasing

• Pharma research increasingly protein interaction and cell focused

• Increasingly becoming Monoclonal antibody / CMO manufacturing base What is Life Sciences?

• Development and manufacture of systems for the purification of biopharmaceuticals

• Technologies and systems for drug discovery research and molecular diagnostics

• Technologies to provides visibility of early trends such as cell therapy

Business advantages• Preferred supplier to most Biopharma/Pharma

companies

• Strong franchise in BioProcess for biopharmamanufacturing

• Breakthrough Technologies for Cellular and Protein Sciences

• New Technologies from Biacore acquisition key in BioPharma drug discovery

$1.2B Revenues

Bioprocess

Protein Scs

Discovery Scs

Genomic Scs

SvcsBia

21GE Healthcare

GE Healthcare Globalization

$7+ B Est. International Sales … 15+% AAGR

Over 50% of Employees outside of US

Emerging countries represent a major growth platform…

• China 10-15%• India 15-20%• SEA 20-25%• MEA 20-25%• EE 15-20%

$16.9

Regional Sales Mix

Americas Japan

China

Europe

MEAROA• ~45% revenues from outside the US

22GE Healthcare

GE Healthcare Int’l Financial Outlook

'00 '06 E

Europe

Japan

ChinaAGM

Revenues

DriversEurope• PPP gaining momentum ... UK, Ib, Ger, It.• EU Cohesion to focus on under avg regions• IT growth area

MEA• Entrepreneurs• Emerging medical insurance• Oil money and financing

Japan• High-end reimbursement up … replacements• Specialization ... DIC’s & Women’s ctrs• COE for compact products

China• Gov’t slowing purchases in near term• Health insurance coverage to grow from

25% to 80% by ‘10• Value outpacing premium

AGM• India gov’t spend, PPP, entrepreneurs• Malaysia, Vietnam building infrastructure• Steady growth in Korea/ANZ

~$7+B

~$3BMEA

23GE Healthcare

The Developing WorldHuge Healthcare Needs …• Large population w/o access to

Healthcare … India, China, Africa• Undeveloped Healthcare

Infrastructure … EE, MEA• Financing needs … access to funding

… Emerging Growth Drivers• Privatization trends … Entrepreneurs• New EU10 Infrastructure investments• MEA modernization projects• Value technologies • Loans and grants

Go Big GE Opportunities … • Company to Country

• Concessional Loans & SKD’s

• Financing & Equity investments

• Rural Health+

'00 '06 E

~$2.5B

~$1B

Revenues

24GE Healthcare

Only GE Healthcare

• The only wing to wing diagnostics company

• Clear Leader in Molecular Imaging, Medical Diagnostics, Diagnostic Imaging, Healthcare IT, Services, Clinical Systems, Protein Separations

• Uniquely capable of delivering clinical outcomes and better healthcare economics

• Real scale… R&D $1B+, global reach, broadest distribution

• Great integration success…more to come

Healthcare Re-imagined

25GE Healthcare

10%+

15%+

2005 2006 E

Revenue

OP

~$2.7

~$15

• Stronger, more balanced GE Healthcare portfolio

• Leading position in Healthcare IT

• Faster growth through disease focus

• Scale and strong growth in emerging markets

• Strong global footprint

• Unmatched Services capability

• Delivering clinical efficacy and healthcare system efficiency

GE Healthcare … Momentum for 2006

($B) ~$17

~3.2B

26GE Healthcare